Concepedia

Jennifer H. Yearley

JH

Statistics

Publications

60

Citations

21.7K

H-Index

35

Active since

2004

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Pennsylvania

Harvard University

University of Chicago

New England Biolabs (United States)

Jennifer H. Yearley is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, cancer immunotherapy, and immunology.

Publications per year

2004–2025

60

Publications

60

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text

, , +14

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text

, , +17

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations

, , +17

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul Nghiem, Shailender Bhatia, Evan J. Lipson et al. · New England Journal of Medicine · 2016 · 1.2K citations · Full text

, , +17

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

Jonathan Sherlock, Barbara Joyce-Shaikh, Scott Turner et al. · Nature Medicine · 2012 · 1K citations

, , +13

1–5 of 60